Skip to main content
. 2020 Sep 16;40(9):BSR20191850. doi: 10.1042/BSR20191850

Figure 3. SEPT2 was a target gene of miR-195-5p in prostate cancer.

Figure 3

(A) The binding sites between miR-195-5p and SEPT2 were predicted by starBase. (B) RT-qPCR assay was operated to detect the expression of SEPT2. (C) Luciferase reporter assay was adopted to confirm the binding capability between miR-195-5p and SEPT2. (D) RNA pull down assay verified the binding abilities between miR-195-5p and LINC00473 (or SEPT2) (E) Nuclear–cytoplasmic fractionation assay was used to detect the subcellular location of LINC00473, miR-195-5p and SEPT2. (F) RT-qPCR assay was employed to test SEPT2 expression; **P<0.01.